ZA201304139B - Combination - Google Patents

Combination

Info

Publication number
ZA201304139B
ZA201304139B ZA2013/04139A ZA201304139A ZA201304139B ZA 201304139 B ZA201304139 B ZA 201304139B ZA 2013/04139 A ZA2013/04139 A ZA 2013/04139A ZA 201304139 A ZA201304139 A ZA 201304139A ZA 201304139 B ZA201304139 B ZA 201304139B
Authority
ZA
South Africa
Prior art keywords
combination
Prior art date
Application number
ZA2013/04139A
Other languages
English (en)
Inventor
Rakesh Kumar
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of ZA201304139B publication Critical patent/ZA201304139B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2013/04139A 2011-01-11 2013-06-06 Combination ZA201304139B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161431508P 2011-01-11 2011-01-11
PCT/US2012/020863 WO2012097021A1 (en) 2011-01-11 2012-01-11 Combination

Publications (1)

Publication Number Publication Date
ZA201304139B true ZA201304139B (en) 2014-02-26

Family

ID=46507420

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/04139A ZA201304139B (en) 2011-01-11 2013-06-06 Combination

Country Status (15)

Country Link
US (6) US20130288984A1 (OSRAM)
EP (1) EP2663189B1 (OSRAM)
JP (1) JP6100700B2 (OSRAM)
KR (1) KR20140053836A (OSRAM)
CN (1) CN103298345B (OSRAM)
AU (1) AU2012205601B2 (OSRAM)
BR (1) BR112013017722A2 (OSRAM)
CA (1) CA2824201A1 (OSRAM)
EA (1) EA029000B1 (OSRAM)
ES (1) ES2689760T3 (OSRAM)
IL (1) IL227097B (OSRAM)
MX (1) MX356704B (OSRAM)
SG (2) SG191724A1 (OSRAM)
WO (1) WO2012097021A1 (OSRAM)
ZA (1) ZA201304139B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105792825A (zh) * 2013-10-01 2016-07-20 诺华股份有限公司 组合
WO2015069266A1 (en) * 2013-11-07 2015-05-14 Flynn Daniel L Methods for inhibiting tie2 kinase useful in the treatment of cancer
AU2019216351B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
CN111818915B (zh) 2018-01-31 2024-05-24 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
KR20250057151A (ko) 2019-12-30 2025-04-28 데시페라 파마슈티칼스, 엘엘씨 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의조성물
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6328590B1 (en) 2000-07-20 2001-12-11 Emc Corporation Methods and apparatus for controlling attachment of an electronic module with a circuit board connector
ES2551293T3 (es) * 2004-03-24 2015-11-17 Abbvie Inc. Inhibidores de quinasas de pirazol tricíclicos
US8324230B2 (en) 2004-10-13 2012-12-04 Pfizer Inc. Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-Yl]-N-(2-hydroxyethyl)-4-methylbenzamide
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
AU2006282896A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1840114A1 (en) 2006-03-30 2007-10-03 LTB4 Sweden AB Crystalline Leukotriene B4
WO2007115286A2 (en) 2006-04-05 2007-10-11 Novartis Ag. Combinations of therapeutic agents for treating cancer
WO2007122686A1 (ja) 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. ベンズイミダゾール化合物
NZ597830A (en) 2006-08-25 2013-02-22 Cougar Biotechnology Inc Methods and compositions for treating cancer comprising abiraterone acetate and prednisone
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
JP4299327B2 (ja) 2006-08-31 2009-07-22 トヨタ自動車株式会社 可変バルブタイミング装置
WO2008094321A2 (en) 2006-10-04 2008-08-07 Universtiy Of South Florida Akt sensitization of cancer cells
EP2079714B1 (de) 2006-10-13 2012-09-26 Basf Se Hydrate des 2-chlor-5-ý3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluormethyl)-1-(2h)-pyrimidinyl¨-4-fluor-n-ýýmethyl-(1-methylethyl)amino¨sulfonyl¨benzamids
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
ES2522365T3 (es) 2007-10-11 2014-11-14 Astrazeneca Ab Derivados de pirrolo [2,3-D] pirimidina como inhibidores de proteína quinasas B
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
DE102008044901A1 (de) 2008-08-29 2010-03-04 Siemens Aktiengesellschaft Verfahren und Vorrichtung zur Auswahl eines Bestrahlungsplans sowie Bestrahlungsanlage
UA106740C2 (uk) 2009-01-30 2014-10-10 Глаксосмітклайн Ллс Кристалічний гідрохлорид n-{(1s)-2-аміно-1-[(3-фторфеніл)метил]етил}-5-хлор-4-(4-хлор-1-метил-1h-піразол-5-іл)-2-тіофенкарбоксаміду
WO2010149755A1 (en) 2009-06-26 2010-12-29 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
BR112012008274A2 (pt) 2009-10-08 2015-09-22 Glaxosmithkline Llc combinação
SG10201504303SA (en) 2011-04-01 2015-07-30 Genentech Inc Combinations Of AKT Inhibitor Compounds And Chemotherapeutic Agents, And Methods Of Use
EP2704699A1 (en) 2011-05-03 2014-03-12 University of Rochester Methods for treating prostate cancer
AU2012283775A1 (en) 2011-07-13 2014-01-23 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
HRP20161256T1 (hr) 2011-10-10 2016-11-18 Zach System Postupak priprave 17-supstituiranih steroida
US20140329786A1 (en) 2011-11-30 2014-11-06 Astrazeneca Ab Combination treatment of cancer
CA3218491A1 (en) 2012-06-04 2013-12-12 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
JP6355724B2 (ja) 2013-10-01 2018-07-11 ノバルティス アーゲー がんを治療するためのアフレセルチブと組み合わせたエンザルタミド

Also Published As

Publication number Publication date
WO2012097021A1 (en) 2012-07-19
AU2012205601A1 (en) 2013-08-01
US20120258933A1 (en) 2012-10-11
SG10201600077RA (en) 2016-02-26
CN103298345A (zh) 2013-09-11
EA029000B1 (ru) 2018-01-31
JP2014507412A (ja) 2014-03-27
SG191724A1 (en) 2013-08-30
EA201391027A1 (ru) 2014-01-30
BR112013017722A2 (pt) 2016-07-12
MX356704B (es) 2018-06-11
KR20140053836A (ko) 2014-05-08
EP2663189A4 (en) 2014-06-11
CN103298345B (zh) 2016-12-14
US20150119337A1 (en) 2015-04-30
JP6100700B2 (ja) 2017-03-22
US10449226B2 (en) 2019-10-22
EP2663189A1 (en) 2013-11-20
ES2689760T3 (es) 2018-11-15
IL227097B (en) 2018-02-28
CA2824201A1 (en) 2012-07-19
US20170100449A1 (en) 2017-04-13
US20160375086A1 (en) 2016-12-29
US20160022641A1 (en) 2016-01-28
MX2013008074A (es) 2013-08-09
EP2663189B1 (en) 2018-07-04
US20130288984A1 (en) 2013-10-31
AU2012205601B2 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
GB201118784D0 (en) Djml
EP2754063A4 (en) EXTENSIBILITY OF THE SMB2 PROTOCOL
AP2014007621A0 (en) 2-Thiopyrimidinones
ZA201304139B (en) Combination
PL2606715T3 (pl) Kombinacja prasująco-owijająca
GB201214881D0 (en) Abdeckeinrichtung
DK2770906T3 (en) Applanationstonometer
GB201103926D0 (en) Lock-alarm
GB201210292D0 (en) Hydraulischer antrieb
GB201116007D0 (en) Combination
GB201106339D0 (en) Combination
GB201117693D0 (en) Combination
GB201121105D0 (en) Combination
AP2011000390S (en) Kuppkraft
GB201118750D0 (en) Azaphthalocyanines
GB201102519D0 (en) Mirrorcane
GB201102066D0 (en) Scottscraper
GB201101931D0 (en) Kerbknight
GB201101772D0 (en) Hat-Pack
GB201101269D0 (en) Hyging
GB201101204D0 (en) Swiftnut
GB201105785D0 (en) Thermo-Symbiotic-Gaming
GB201106767D0 (en) McDoughnut
GB201104071D0 (en) Eds-max
GB201108148D0 (en) Smartcup